| |
April 3-4, 2023 | San Diego, CA The only west coast event exclusively for life science communicators to share best practices, benchmarks, and tools, as well as network with peers. Early Bird Rate Ends January 27th.
|
|
Today's Big NewsJan 24, 2023 |
| By Heather Landi Amazon's pharmacy business is rolling out a new subscription service that enables Prime members to get unlimited generic medications for a flat fee of $5 a month. |
|
|
|
By Gabrielle Masson There's a time and a place for everything, and right now might be the time for venture debt as biotechs operate on razor-thin margins. |
By Andrea Park After issuing near-monthly safety warnings related to its discontinued HeartWare Ventricular Assist Device (HVAD) last year, Medtronic is already continuing the trend in 2023. |
By Zoey Becker Novartis, after falling short at the federal appeals court, asked the Supreme Court to take up its Gilenya patent case. The company argues an appeals judge's retirement affected its case. |
|
Thursday, February 16, 2023 | 11am ET / 8am PT Join this session as a panel of experts discusses the realized benefits of using AI and communication tools to redefine the care pathway to detect stroke and streamline the patient journey to direct more patients for cardiology follow-up. Register now.
|
|
By Angus Liu Ipsen’s near-$1 billion deal for Albireo was among a trio of biopharma acquisitions that opened this year’s J.P. Morgan Healthcare Conference. But Ipsen only got a chance to bid thanks to a sudden withdrawal by another company, and the French pharma fought hard when the opportunity presented itself. |
By Nick Paul Taylor Finch Therapeutics is throwing in the towel. Shortly after getting its phase 3 clinical trial back on track, the microbiome biotech has decided to stop the study and seek to offload assets in the face of a frosty funding forecast and slow enrollment. |
By Paige Minemyer Elevance Health has inked a deal to acquire Blue Cross and Blue Shield of Louisiana, with the Pelican State insurer joining the Anthem Blue Cross affiliated plans. |
By Andrea Park After spending much of last year shifting resources toward an update to its DPNCheck screening device for peripheral neuropathy, NeuroMetrix is ready to reap the rewards of that investment. |
By Kevin Dunleavy Even though Eli Lilly has yet to begin manufacturing at its ballyhooed plant at Research Triangle Park in North Carolina, it now has plans to expand it to the tune of an additional $450 million. That’s how much more Lilly says it will pour into the facility, along with an increase of at least 100 more employees, to help meet an expected surge in demand for new Type 2 diabetes treatment Mounjaro, which the company anticipates will soon be approved to treat obesity. |
By Max Bayer Johnson & Johnson continued to trim away at early-stage cancer prospects, culling a prostate and solid tumor asset, respectively. The decision comes as the company was quiet on the specific timing of looming 2023 readouts. |
By Robert King CMMI aims to release three to four new advance primary care payment models this year and another model enabling states to oversee the total cost of care for Medicare beneficiaries, Director Liz Fowler shared. |
By Conor Hale Asensus Surgical has secured a European approval that builds upon the machine vision capabilities of its previously greenlighted robotic surgery hardware. |
By Annalee Armstrong Cassava Sciences, which spent 2022 trying to prove the integrity of its Alzheimer’s disease program, is trumpeting a phase 2 win for simufilam in an open-label study—but investors aren’t convinced. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer. |
|
|---|
|
|
|
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk and addressing the specific drug supply challenges commonly associated with adaptive, decentralized, platform and other complex trial designs. Register now.
|
|
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
